Brazil's Limited Legal Framework On Biosimilar Interchangeability Could Actually Help Sponsors
Executive Summary
Anvisa currently has no legislative authority to tell the Ministry of Health to refrain from providing biosimilar medications interchangeably, giving drugmakers an expanded opportunity to access Brazil's large patient population.